Waldert Matthias, Haitel Andrea, Marberger Michael, Katzenbeisser Daniela, Ozsoy Mehmet, Stadler Elisabeth, Remzi Mesut
Department of Urology, Medical University of Vienna, Vienna, Austria.
BJU Int. 2008 Nov;102(10):1381-4. doi: 10.1111/j.1464-410X.2008.07999.x. Epub 2008 Sep 8.
To compare the pathological features of clear cell renal cell carcinoma (ccRCC) with papillary RCC (pRCC) and further differentiate type I and II pRCC as independent prognosticators for survival.
From September 1994 to February 2007 557 RCCs were treated and reviewed. All patients underwent radical nephrectomy or nephron-sparing surgery. We reviewed patient data and correlated RCC subtypes to tumour size, pathological stage, nuclear grade, and 5-year cancer-specific survival (CSS). pRCC was re-evaluated in to type I and II. The 2002 Tumour-Node-Metastasis and Fuhrman classifications were used.
In all, 391 (70%) patients had ccRCC, 96 (17%) had pRCC, 34 (6%) had chromophobe RCC, seven (1%) had ductus Bellini RCC and 29 (5%) had unclassified RCC. Upon re-evaluation 34 patients had type I pRCC and 62 had type II. The pRCCs were significantly smaller than the ccRCCs, at a mean (sd) of 4.5 (2.5) cm vs 5 (2.9) cm (P = 0.013), and multifocal (25% vs 12%, P = 0.001). Whereas patients with ccRCC had significantly more primary metastases (12% vs 3%, P = 0.014). The mean (sd) follow-up was 42.3 (41.4) months. The 5-year CSS for M0 patients was 84% for ccRCC and 90% for pRCC (P = 0.573). At multivariate analyses predictors for 5-year CSS were only tumour size (hazard ratio, HR 2.6, P < 0.001), pathological stage (HR 3.9, P < 0.001) and nuclear grade (HR 2.7, P < 0.001). The type I and II pRCCs had significantly different lymphovascular invasion (LVI) and 5-year CSS rates (94% vs 74%, P = 0.03).
The ccRCCs were significantly larger at diagnosis than the pRCCs. The histological subtype (pRCC vs ccRCC) had no impact on the 5-year CSS in multivariate analyses. The type I and II pRCCs had similar histopathological features except for a significant difference in LVI. However, the 5-year CSS was significantly different in type I and II pRCC.
比较透明细胞肾细胞癌(ccRCC)与乳头状肾细胞癌(pRCC)的病理特征,并进一步区分I型和II型pRCC作为独立的生存预后指标。
对1994年9月至2007年2月期间接受治疗并进行回顾的557例肾细胞癌患者进行研究。所有患者均接受了根治性肾切除术或保留肾单位手术。我们回顾了患者数据,并将肾细胞癌亚型与肿瘤大小、病理分期、核分级和5年癌症特异性生存率(CSS)进行关联。pRCC被重新评估为I型和II型。采用2002年肿瘤-淋巴结-转移和Fuhrman分类法。
总共391例(70%)患者为ccRCC,96例(17%)为pRCC,34例(6%)为嫌色性肾细胞癌,7例(1%)为Bellini管癌,29例(5%)为未分类肾细胞癌。重新评估后,34例患者为I型pRCC,62例为II型。pRCC明显小于ccRCC,平均(标准差)分别为4.5(2.5)cm和5(2.9)cm(P = 0.013),且多灶性更多(25%对12%,P = 0.001)。而ccRCC患者有更多的原发性转移(12%对3%,P = 0.014)。平均(标准差)随访时间为42.3(41.4)个月。M0患者的5年CSS,ccRCC为84%,pRCC为90%(P = 0.573)。多因素分析显示,5年CSS的预测因素仅为肿瘤大小(风险比,HR 2.6,P < 0.001)、病理分期(HR 3.9,P < 0.001)和核分级(HR 2.7,P < 0.001)。I型和II型pRCC的淋巴管侵犯(LVI)和5年CSS率有显著差异(94%对74%,P = 0.03)。
ccRCC在诊断时明显大于pRCC。组织学亚型(pRCC与ccRCC)在多因素分析中对5年CSS无影响。I型和II型pRCC除LVI有显著差异外,具有相似的组织病理学特征。然而,I型和II型pRCC的5年CSS有显著差异。